First Light Biosciences is now

First Light Diagnostics

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detection of pathogens that can cause life-threatening infections. Our antimicrobial susceptibility tests will help ensure that patients suffering from infection receive appropriate antibiotic treatment options in hours and not days compared to current practices. Leveraging our highly differentiated MultiPath™ technology, our products strive to save lives, lower healthcare costs, improve antibiotic stewardship, and prevent the spread of antibiotic drug-resistance.

Recent News & Upcoming Events

First Light Diagnostics MultiPath™ Platform to be Showcased at AACC 2019

CHELMSFORD, Mass., July 31, 2019 (Newswire.com) – ​First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced their participation at the American Association for Clinical Chemistry’s (AACC) 71st Annual Scientific Meeting & Clinical Lab Expo in Anaheim, California from August 4-8. First Light Diagnostics will…

Read More

First Light Diagnostics Receives Technology Innovation Leader Award at Frost & Sullivan Gala

Chelmsford, MA – (July 24th, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, formally received their award for Technology Innovation at the 2019 Frost & Sullivan Excellence in Best Practices Awards Gala on July 17th at the San Diego Marriott La Jolla,…

Read More

First Light Adds New Multimedia to Website

New videos include 1-1 clinician interviews and detailed product tour Chelmsford, MA – (July 10th, 2019) First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the introduction of new multimedia content on the homepage of the First Light Diagnostics website. The new content…

Read More

First Light Diagnostics Announces Closing of a $4.5 million Debt Financing

Additional funds to support the company’s diagnostic platform initiatives Chelmsford, MA – (June 19, 2019) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis and treatment of life-threatening, antibiotic-resistant infections, today announced the closing of a $4.5 million debt financing. This includes a Lease Line with CSC…

Read More

First Light Diagnostics to Showcase MultiPath™ Platform at ASM Microbe 2019

CHELMSFORD, Mass., June 6, 2019 (Newswire.com) –  First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced its participation at the American Society for Microbiology’s ASM Microbe 2019 Event in San Francisco, California, from June 20-24. First Light Diagnostics will be exhibiting in the Innovation Zone, the newest addition…

Read More
How First Light Diagnostics and their MultiPathTM Platform Can Help Patients Receive the Right Therapy at the Onset of Infection
Medical Practitioners Discuss the Causes and Impacts of Antibiotic Resistance and the Effect Rapid Results can Have to Address the Problem

What Sets Us Apart?

Our MultiPath technology is advancing the field of rapid diagnostics in several key areas:
Time to Result

Time to Result

The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…directly from patient sample.

Automation

Automation

The MultiPath analyzer is a fully automated “sample-to-answer” platform. By combining this level of automation with rapid tests, we can perform up to 40 antimicrobial susceptibility tests or 200 identification tests in a single 8-hour shift.

Versatility

Versatility

The MultiPath platform is unique in its ability to rapidly identify a broad range of pathogens, detect toxins and biomarkers with high sensitivity, and perform rapid phenotypic antimicrobial susceptibility testing.

Menu